XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Stockholders’ (Deficit) Equity
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Treasury stock, at cost
Non-controlling interest
Balance at Dec. 31, 2022 $ 103,864 $ 100,017 $ 12 $ 787,130 $ (688,492) $ 1,371 $ (4) $ 3,847
Balance (in Shares) at Dec. 31, 2022     106,417,265          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of RSUs (in shares)     619,387          
Issuance of RSAs (in shares)     27,744          
Exercise of common stock options 25 25   25        
Exercise of common stock options (in Shares)     91,258          
Stock-based compensation expense 4,548 4,548   4,548        
Net loss (16,349) (16,349)     (16,349)      
Foreign currency translation adjustment 432 432       432    
Balance at Mar. 31, 2023 92,520 88,673 $ 12 791,703 (704,841) 1,803 (4) 3,847
Balance (in Shares) at Mar. 31, 2023     107,155,654          
Balance at Dec. 31, 2022 103,864 100,017 $ 12 787,130 (688,492) 1,371 (4) 3,847
Balance (in Shares) at Dec. 31, 2022     106,417,265          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (55,339)              
Foreign currency translation adjustment (218)              
Balance at Sep. 30, 2023 84,105 80,258 $ 12 822,928 (743,831) 1,153 (4) 3,847
Balance (in Shares) at Sep. 30, 2023     108,976,312          
Balance at Mar. 31, 2023 92,520 88,673 $ 12 791,703 (704,841) 1,803 (4) 3,847
Balance (in Shares) at Mar. 31, 2023     107,155,654          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of RSUs (in shares)     605,975          
Issuance of RSAs (in shares)     376,325          
Exercise of common stock options 13 13   13        
Exercise of common stock options (in Shares)     46,583          
Stock-based compensation expense 3,697 3,697   3,697        
Issuance of common warrants 14,598 14,598   14,598        
Net loss (15,770) (15,770)     (15,770)      
Foreign currency translation adjustment 20 20       20    
Balance at Jun. 30, 2023 95,078 91,231 $ 12 810,011 (720,611) 1,823 (4) 3,847
Balance (in Shares) at Jun. 30, 2023     108,184,537          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of RSUs (in shares)     260,215          
Issuance of RSAs (in shares)     24,500          
Exercise of common stock options 28 28   28        
Exercise of common stock options (in Shares)     98,829          
Stock-based compensation expense 3,762 3,762   3,762        
Exercise of common warrants 882 882   882        
Exercise of common warrants (in shares)     408,231          
Issuance of common warrants 8,245 8,245   8,245        
Net loss (23,220) (23,220)     (23,220)      
Foreign currency translation adjustment (670) (670)       (670)    
Balance at Sep. 30, 2023 84,105 80,258 $ 12 822,928 (743,831) 1,153 (4) 3,847
Balance (in Shares) at Sep. 30, 2023     108,976,312          
Balance at Dec. 31, 2023 80,096 78,734 $ 12 837,416 (760,227) 2,198 (665) 1,362
Balance (in Shares) at Dec. 31, 2023     111,132,222          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of RSUs (in shares)     1,226,498          
Issuance of RSAs (in shares)     38,130          
Exercise of common stock options 544 544   544        
Exercise of common stock options (in Shares)     186,074          
Reclassification of warrant liability to common stock warrants 2,468 2,468   2,468        
Stock-based compensation expense 6,293 6,293   6,293        
Net loss (31,610) (31,610)     (31,610)      
Foreign currency translation adjustment (522) (522)       (522)    
Balance at Mar. 31, 2024 57,269 55,907 $ 12 846,721 (791,837) 1,676 (665) 1,362
Balance (in Shares) at Mar. 31, 2024     112,582,924          
Balance at Dec. 31, 2023 80,096 78,734 $ 12 837,416 (760,227) 2,198 (665) 1,362
Balance (in Shares) at Dec. 31, 2023     111,132,222          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (69,609)              
Foreign currency translation adjustment 304              
Balance at Sep. 30, 2024 65,571 65,571 $ 14 893,584 (829,836) 2,502 (693)
Balance (in Shares) at Sep. 30, 2024     127,545,321          
Balance at Mar. 31, 2024 57,269 55,907 $ 12 846,721 (791,837) 1,676 (665) 1,362
Balance (in Shares) at Mar. 31, 2024     112,582,924          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of RSUs 1 1 $ 1          
Vesting of RSUs (in shares)     294,589          
Issuance of RSAs (in shares)     231,323          
Exercise of common stock options 1,106 1,106   1,106        
Exercise of common stock options (in Shares)     438,118          
Reclassification of warrant liability to common stock warrants 4,308 4,308   4,308        
Stock-based compensation expense 2,792 2,792   2,792        
Exercise of common warrants 21,036 21,036 $ 1 21,035        
Exercise of common warrants (in shares)     9,738,930          
Interest payment through issuance of shares of common stock 1,867 1,867   1,867        
Interest payment through issuance of shares of common stock (in Shares)     237,722          
Redemption of NCI 67 1,429   1,429       (1,362)
Redemption of NCI (in Shares)     397,037          
Shares of Common Stock received from settlement of employee receivables (28) (28)         (28)  
Net loss (24,390) (24,390)     (24,390)      
Foreign currency translation adjustment (179) (179)       (179)    
Balance at Jun. 30, 2024 63,849 63,849 $ 14 879,258 (816,227) 1,497 (693)  
Balance (in Shares) at Jun. 30, 2024     123,917,627          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Shares of Common Stock received from settlement of employee receivables (in Shares)     (3,016)          
Vesting of RSUs (in shares)     243,481          
Exercise of common stock options 232 232   232      
Exercise of common stock options (in Shares)     207,977          
Reclassification of warrant liability to common stock warrants 4,747 4,747   4,747        
Stock-based compensation expense 2,487 2,487   2,487        
Exercise of common warrants 6,860 6,860   6,860      
Exercise of common warrants (in shares)     3,176,236          
Redemption of NCI     $ (1,400)          
Redemption of NCI (in Shares)     397,037          
Net loss (13,609) (13,609)     (13,609)      
Foreign currency translation adjustment 1,005 1,005       1,005    
Balance at Sep. 30, 2024 $ 65,571 $ 65,571 $ 14 $ 893,584 $ (829,836) $ 2,502 $ (693)
Balance (in Shares) at Sep. 30, 2024     127,545,321